Table 1. Baseline characteristics of the enrolled COVID-19-infected patients according to HBV infection with or without antiviral agent treatment.
Characteristics | All patients (n = 19,160) | HBV-infected (n = 675) | Not HBV-infected (n = 18,485) | P value | Anti-viral agents user (n = 138) | Anti-viral agents non-user (n = 537) | P value | |
---|---|---|---|---|---|---|---|---|
Age, yr | 52.8 ± 12.5 | 59.3 ± 15.7 | 52.6 ± 21.7 | < 0.001 | 58.5 ± 12.0 | 59.5 ± 16.5 | 0.170 | |
Range | < 0.001 | 0.009 | ||||||
≤ 39 | 5,604 (29.2) | 80 (11.9) | 5,524 (29.9) | 10 (7.2) | 70 (13.0) | |||
40–65 | 7,695 (40.2) | 355 (52.6) | 7,340 (39.7) | 88 (63.8) | 267 (49.7) | |||
≥ 65 | 5,861 (30.6) | 240 (35.6) | 5,621 (30.4) | 40 (29.0) | 200 (37.3) | |||
Sex | 0.290 | 0.017 | ||||||
Male | 9,065 (47.3) | 333 (49.3) | 8,732 (47.2) | 81 (58.7) | 252 (46.9) | |||
Female | 10,095 (52.7) | 342 (50.7) | 9,753 (52.8) | 57 (41.3) | 285 (53.1) | |||
Comorbidity | ||||||||
Diabetes mellitus | 6,804 (35.5) | 395 (58.5) | 6,409 (34.7) | < 0.001 | 71 (51.5) | 324 (60.3) | 0.066 | |
Hypertension | 7,239 (37.8) | 336 (49.8) | 6.903 (37.3) | < 0.001 | 62 (44.9) | 274 (51.0) | 0.215 | |
Cerebrovascular disease | 3,001 (15.7) | 141 (20.9) | 2,860 (15.5) | < 0.001 | 24 (17.4) | 117 (21.8) | 0.291 | |
Chronic pulmonary disease | 6,120 (31.9) | 275 (40.7) | 5,845 (31.6) | < 0.001 | 41 (29.7) | 234 (43.6) | 0.003 | |
Chronic renal disease | 781 (4.1) | 64 (9.5) | 717 (3.9) | < 0.001 | 8 (5.8) | 56 (10.4) | 0.105 | |
Liver cirrhosis | 377 (2.0) | 129 (19.1)) | 248 (1.3) | < 0.001 | 64 (46.4) | 65 (12.1) | < 0.001 | |
Cancer | 2,947 (15.4) | 311 (46.1) | 2,636 (14.3) | < 0.001 | 92 (66.7) | 219 (40.8) | < 0.001 | |
Hepatocellular carcinoma | 498 (2.6) | 155 (23.0) | 343 (1.9) | < 0.001 | 67 (48.6) | 88 (16.4) | < 0.001 |
Data are shown as number (%) or mean ± SD. P values were calculated using the student’s t-test or the χ2 or Fischer exact test, as appropriate.
COVID-19 = coronavirus disease 2019, HBV = hepatitis B virus.